Moderna (MRNA) shares opened in the green this morning after the U.S. Food and Drug Administration (FDA) approved mFLUSIVA (mRNA-1010), the company’s seasonal influenza vaccine for adults aged 50 and older.
The regulatory announcement makes mFLUSIVA the world’s very first market-cleared mRNA flu vaccine. In total, the pharmaceutical giant now has four FDA-approved products in its portfolio.